These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 31673229)

  • 61. Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures.
    Hidaka H; Kurosaki M; Tanaka H; Kudo M; Abiru S; Igura T; Ishikawa T; Seike M; Katsube T; Ochiai T; Kimura K; Fukuhara T; Kano T; Nagata T; Tanaka K; Kurokawa M; Yamamoto K; Osaki Y; Izumi N; Imawari M
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1192-1200. PubMed ID: 30502505
    [TBL] [Abstract][Full Text] [Related]  

  • 62. AGA Clinical Practice Update: Coagulation in Cirrhosis.
    O'Leary JG; Greenberg CS; Patton HM; Caldwell SH
    Gastroenterology; 2019 Jul; 157(1):34-43.e1. PubMed ID: 30986390
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Lusutrombopag: First Global Approval.
    Kim ES
    Drugs; 2016 Jan; 76(1):155-8. PubMed ID: 26666417
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Thrombocytopenia associated with chronic liver disease.
    Afdhal N; McHutchison J; Brown R; Jacobson I; Manns M; Poordad F; Weksler B; Esteban R
    J Hepatol; 2008 Jun; 48(6):1000-7. PubMed ID: 18433919
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Romiplostim for the management of perioperative thrombocytopenia.
    Al-Samkari H; Marshall AL; Goodarzi K; Kuter DJ
    Br J Haematol; 2018 Jul; 182(1):106-113. PubMed ID: 29767837
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Thrombocytopenia in chronic liver disease.
    Peck-Radosavljevic M
    Liver Int; 2017 Jun; 37(6):778-793. PubMed ID: 27860293
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Romiplostim and Eltrombopag in Immune Thrombocytopenia as a Second-Line Treatment.
    Bidika E; Fayyaz H; Salib M; Memon AN; Gowda AS; Rallabhandi B; Cancarevic I
    Cureus; 2020 Aug; 12(8):e9920. PubMed ID: 32968581
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The impact of thrombopoietin on clinical practice.
    Basser R
    Curr Pharm Des; 2002; 8(5):369-77. PubMed ID: 12069375
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Management strategies for chronic liver disease-related thrombocytopenia].
    Qian JD; Yao TT; Wang Y; Wang GQ
    Zhonghua Gan Zang Bing Za Zhi; 2021 Sep; 29(9):896-899. PubMed ID: 34638215
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia.
    Jurczak W; Chojnowski K; Mayer J; Krawczyk K; Jamieson BD; Tian W; Allen LF
    Br J Haematol; 2018 Nov; 183(3):479-490. PubMed ID: 30191972
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Thrombopoietin receptor agonist is more effective than platelet transfusion for chronic liver disease with thrombocytopenia, shown by propensity score matching.
    Furuichi Y; Takeuchi H; Yoshimasu Y; Kasai Y; Abe M; Itoi T
    Hepatol Res; 2020 Sep; 50(9):1062-1070. PubMed ID: 32510789
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.
    Afdhal NH; Giannini EG; Tayyab G; Mohsin A; Lee JW; Andriulli A; Jeffers L; McHutchison J; Chen PJ; Han KH; Campbell F; Hyde D; Brainsky A; Theodore D;
    N Engl J Med; 2012 Aug; 367(8):716-24. PubMed ID: 22913681
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures.
    Takada H; Kurosaki M; Nakanishi H; Takahashi Y; Itakura J; Tsuchiya K; Yasui Y; Tamaki N; Takaura K; Komiyama Y; Higuchi M; Kubota Y; Wang W; Okada M; Shimizu T; Watakabe K; Enomoto N; Izumi N
    PLoS One; 2019; 14(2):e0211122. PubMed ID: 30768601
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Management of thrombocytopenia due to liver cirrhosis: a review.
    Hayashi H; Beppu T; Shirabe K; Maehara Y; Baba H
    World J Gastroenterol; 2014 Mar; 20(10):2595-605. PubMed ID: 24627595
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Eltrombopag Use for Treatment of Thrombocytopenia in a Patient with Chronic Liver Disease and Portal Vein Thrombosis: Case Report.
    Mohamed SE; Yassin MA
    Case Rep Oncol; 2020; 13(2):863-866. PubMed ID: 32884532
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Lusutrombopag: A Review in Thrombocytopenia in Patients with Chronic Liver Disease Prior to a Scheduled Procedure.
    Shirley M; McCafferty EH; Blair HA
    Drugs; 2019 Oct; 79(15):1689-1695. PubMed ID: 31529283
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Primary Hemostasis in Chronic Liver Disease and Cirrhosis: What Did We Learn over the Past Decade?
    van Dievoet MA; Eeckhoudt S; Stephenne X
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32384725
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Efficacy and safety of repeated use of lusutrombopag prior to radiofrequency ablation in patients with recurrent hepatocellular carcinoma and thrombocytopenia.
    Ishikawa T; Okoshi M; Tomiyoshi K; Kojima Y; Horigome R; Imai M; Nozawa Y; Iwanaga A; Sano T; Honma T; Yoshida T
    Hepatol Res; 2019 May; 49(5):590-593. PubMed ID: 30602063
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, Safety, and Tolerability of Avatrombopag in Healthy Japanese and White Subjects.
    Nomoto M; Pastino G; Rege B; Aluri J; Ferry J; Han D
    Clin Pharmacol Drug Dev; 2018 Feb; 7(2):188-195. PubMed ID: 28339166
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effectiveness of Lusutrombopag in Patients with Mild to Moderate Thrombocytopenia.
    Tsuji Y; Kawaratani H; Ishida K; Kaya D; Kubo T; Fujinaga Y; Sawada Y; Takaya H; Shimozato N; Kaji K; Namisaki T; Moriya K; Akahane T; Yoshiji H
    Dig Dis; 2020; 38(4):329-334. PubMed ID: 31655803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.